This has left J&J vaccine recipients in limbo, especially the immunocompromised who may be at risk from the Indian ‘Delta’ variant despite being fully vaccinated.
The U.S. Food and Drug Administration (FDA) says they plan to eventually approve booster shots for J&J recipients, but can not yet do so due to a lack of data.
But some people who got the J&J shot have resorted to receiving extra doses before being authorized.
The 13.9 million recipients of the Johnson & Johnson COVID-19 vaccine have been left in limbo, as they await word on when booster shots will be made available for them
Expert recommends that some J&J recipients concerned about booster shots should contact physician about receiving an additional jab. Pictured: A woman receives a dose of the Johnson & Johnson Covid vaccine from a healthcare worker, August 2021
The agency has yet to give guidance for J&J recipients, though.
While the number of Americans who have received the one-shot vaccine, around 13.9 million, is dwarfed by the nearly 350 million Americans who received the two-shot jobs, this group is still extremely worried.
‘They’re in limbo,’ Dr William Schaffner, an infectious disease expert from Vanderbilt University in Nashville, Tennessee, told the DailyMail.com.
‘It’s a big issue for individuals who received the vaccine. It is a small number in comparison to others, but it is very important to these recipients.’
Schaffner’s medical center in Nashville has been inundated with calls from J&J vaccine recipients worried about the prospect of the Delta variant.
He says that he is especially worried about some immunocompromised people, and specifically HIV patients, who received the one-shot vaccine.
Data on the J&J vaccine are coming in slower than in came in for others, though, meaning health officials do not have the information necessary to make an official recommendation.
Schaffner says there are some way around this.
He insists that while he can not make any blanket recommendations, those who are worried should contact their doctor and discuss the prospect of receiving an additional dose of the Pfizer or Moderna vaccine.
Some physicians are already making that recommendation, and in San Francisco the city’s health department is already offering J&J recipients at
Dr Rochelle Walensky, director of the Centers for Disease Control and Prevention, has reported that at least one million Americans have
The data necessary to make an official recommendation may take some time, though, if it ever does come in.
‘I don’t think we’ll have a great of information on mixing and matching with the J&J [vaccine],’ Schaffner said.
‘I don’t think we’ll have a lot of data about J&J first dose then Pfizer or Moderna second [dose].’
Schaffner does say that data from Europe and the AstraZeneca vaccine could be valuable.
While the J&J vaccine is not exactly the same as its counterpart, it is similar enough that data from across the pond could be used to make a decision in America.